458 related articles for article (PubMed ID: 24138829)
1. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG
Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model.
Chandrasekharan P; Yang CT; Nasrallah FA; Tay HC; Chuang KH; Robins EG
Contrast Media Mol Imaging; 2015; 10(3):237-44. PubMed ID: 25612157
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
Chandrasekharan P; Yong CX; Poh Z; He T; He Z; Liu S; Robins EG; Chuang KH; Yang CT
Biomaterials; 2012 Dec; 33(36):9225-31. PubMed ID: 23026708
[TBL] [Abstract][Full Text] [Related]
4. A new class of Gd-based DO3A-ethylamine-derived targeted contrast agents for MR and optical imaging.
Mishra A; Pfeuffer J; Mishra R; Engelmann J; Mishra AK; Ugurbil K; Logothetis NK
Bioconjug Chem; 2006; 17(3):773-80. PubMed ID: 16704217
[TBL] [Abstract][Full Text] [Related]
5. Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block copolymers having Gd-DOTA; preparations and their control of T(1)-relaxivities and blood circulation characteristics.
Shiraishi K; Kawano K; Maitani Y; Yokoyama M
J Control Release; 2010 Dec; 148(2):160-7. PubMed ID: 20804796
[TBL] [Abstract][Full Text] [Related]
6. In vivo labeling of B16 melanoma tumor xenograft with a thiol-reactive gadolinium based MRI contrast agent.
Menchise V; Digilio G; Gianolio E; Cittadino E; Catanzaro V; Carrera C; Aime S
Mol Pharm; 2011 Oct; 8(5):1750-6. PubMed ID: 21780833
[TBL] [Abstract][Full Text] [Related]
7. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity.
Livramento JB; Weidensteiner C; Prata MI; Allegrini PR; Geraldes CF; Helm L; Kneuer R; Merbach AE; Santos AC; Schmidt P; Tóth E
Contrast Media Mol Imaging; 2006; 1(1):30-9. PubMed ID: 17193598
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
9. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.
Ye Z; Zhou Z; Ayat N; Wu X; Jin E; Shi X; Lu ZR
Contrast Media Mol Imaging; 2016; 11(1):32-40. PubMed ID: 26218648
[TBL] [Abstract][Full Text] [Related]
10. A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.
Adiseshaiah P; Dellinger A; MacFarland D; Stern S; Dobrovolskaia M; Ileva L; Patri AK; Bernardo M; Brooks DB; Zhou Z; McNeil S; Kepley C
Invest Radiol; 2013 Nov; 48(11):745-54. PubMed ID: 23748228
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium complex of DO3A-benzothiazole aniline (BTA) conjugate as a theranostic agent.
Kim HK; Kang MK; Jung KH; Kang SH; Kim YH; Jung JC; Lee GH; Chang Y; Kim TJ
J Med Chem; 2013 Oct; 56(20):8104-11. PubMed ID: 24063520
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable cystamine spacer facilitates the clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging.
Ke T; Feng Y; Guo J; Parker DL; Lu ZR
Magn Reson Imaging; 2006 Sep; 24(7):931-40. PubMed ID: 16916710
[TBL] [Abstract][Full Text] [Related]
13. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
Caravan P
Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
[TBL] [Abstract][Full Text] [Related]
14. Slow clearance gadolinium-based extracellular and intravascular contrast media for three-dimensional MR angiography.
Bremerich J; Colet JM; Giovenzana GB; Aime S; Scheffler K; Laurent S; Bongartz G; Muller RN
J Magn Reson Imaging; 2001 Apr; 13(4):588-93. PubMed ID: 11276103
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and biodistribution study of self-assembled Gd-micelles demonstrating blood-pool contrast enhancement for MRI.
Vorobiev V; Babič A; Crowe LA; Van De Looij Y; Lenglet S; Thomas A; Helm L; Vallée JP; Allémann E
Int J Pharm; 2019 Sep; 568():118496. PubMed ID: 31279053
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Effect of Human Serum Albumin and Fullerene on Gd-DO3A for Tumor-Targeting Imaging.
Zhang Y; Zou T; Guan M; Zhen M; Chen D; Guan X; Han H; Wang C; Shu C
ACS Appl Mater Interfaces; 2016 May; 8(18):11246-54. PubMed ID: 27097822
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and relaxivity studies of a tetranuclear gadolinium(III) complex of DO3A as a contrast-enhancing agent for MRI.
Jebasingh B; Alexander V
Inorg Chem; 2005 Dec; 44(25):9434-43. PubMed ID: 16323930
[TBL] [Abstract][Full Text] [Related]
19. Development of intravascular contrast agents for MRI using gadolinium chelates.
Kittigowittana K; Yang CT; Cheah WC; Chuang KH; Tuang CY; Chang YT; Golay X; Bates RW
ChemMedChem; 2011 May; 6(5):781-7. PubMed ID: 21433294
[TBL] [Abstract][Full Text] [Related]
20. How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity.
Port M; Corot C; Violas X; Robert P; Raynal I; Gagneur G
Invest Radiol; 2005 Sep; 40(9):565-73. PubMed ID: 16118549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
